Bifunctional Pro-antigen Compounds for Solid Tumor Targeting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer immunotherapies, such as CAR T cell therapies, face challenges in effectively targeting solid tumors due to the difficulty in identifying tumor-specific antigens that are unique to cancer cells but not present on normal cells, leading to unintended damage to healthy tissues.

Innovation Solution

Development of bifunctional compounds with a targeting moiety that binds to tumor-associated antigens and a pro-antigen that remains inert in normal cells but activates in the tumor microenvironment due to elevated ROS/RNS levels, allowing CAR T cells to selectively target and eliminate tumor cells while sparing normal cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If CAR T cells are used to target tumor-associated antigens, then therapeutic efficacy against tumors is improved, but normal cells expressing the same antigens are damaged causing harmful side effects

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoiddamage to normal cells

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces a pro-antigen that is预先 masked with a protecting group, making it inactive before treatment. This preliminary inactivation prevents CAR T cells from attacking normal cells. The pro-antigen is designed to be activated only after administration, allowing safe delivery to patients before the therapeutic effect is activated.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent exploits the parameter change of ROS/RNS levels between tumor and normal microenvironments. The pro-antigen's protecting group is designed to be cleaved specifically by elevated ROS/RNS in tumor tissue, transforming the antigen from inactive to active state only where needed. This parameter-based activation resolves the contradiction by spatially controlling therapeutic activity.

Inventive Principle:

Principle #35Parameter changes

2Measurement precision

If tumor-specific antigens are targeted for immunotherapy, then treatment specificity is improved, but difficulty in identifying true tumor-specific antigens worsens

Engineering Contradiction:

Improvetreatment specificityVSAvoididentification of tumor-specific antigens

Core Design Contradiction:

Measurement precisionVSDifficulty of detecting and measuring

Solution Approach 1:

The patent introduces an intermediary activation mechanism (ROS/RNS-cleavable protecting group) between the antigen and CAR T cell recognition. Instead of directly targeting rare tumor-specific antigens, the system uses common tumor-associated antigens combined with a molecular switch that provides the necessary specificity. This intermediary layer solves the identification problem by decoupling antigen selection from specificity requirements.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the mechanical/biological requirement for unique tumor-specific antigens with a chemical activation system. Rather than relying on the rarity and uniqueness of tumor antigens for specificity, the system uses ROS/RNS-cleavable chemical groups to provide conditional activation, substituting chemical mechanisms for biological specificity requirements.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Measurement precision

If pro-antigen is designed to be activated by ROS/RNS in tumor microenvironment, then selectivity for tumor cells is improved, but complexity of compound structure worsens

Engineering Contradiction:

ImproveselectivityVSAvoidcompound structure

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent extracts the activation function from the antigen itself and places it in a separate protecting group that can be independently optimized. The antigen portion maintains simple, well-characterized structures for CAR T cell recognition, while the ROS/RNS-cleavable protecting group is attached as a modular functional element. This separation reduces overall complexity by allowing independent optimization of each component.

Inventive Principle:

Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enhances the therapeutic efficacy of CAR T cell therapies by selectively targeting tumor cells, reducing side effects on normal tissues, and improving treatment outcomes for solid tumors by leveraging the unique microenvironmental conditions of tumors.

Implementation Method 1

The pro-antigen is designed to be inert in normal (non-diseased) cells and tissues, and to become activated (or 'unmasked' or 'uncaged') in the presence of ROS/RNS

Methodology Applied

Scientific EffectOxidation: Oxidation